Endoscopy, the standard for detecting esophageal precancer, is quite an invasive procedure — so a lot of people who should be screened end up never being tested. Lucid Diagnostics is trying to solve this problem by selling a quick, office-based diagnostic.
By addressing each community’s unique needs with tailored, culturally responsive care and cross-sector collaboration, we can empower healthcare providers to drive lasting, equitable outcomes.
Transitioning to PDPM models significantly shifted the healthcare industry. By replacing the RUG system, healthcare providers cut waste and more accurately reflect the care each patient received.
Cancer treatment is one area that could benefit significantly from AI, as it can aid in early detection, precise diagnosis, and personalized treatment plans.
Cytovale, a San Francisco-based medical diagnostics company, raised $84 million in Series C funds to advance the commercialization of its diagnostic test for early sepsis detection. Using standard blood draws, the test provides results in under 10 minutes. It is meant to detect sepsis in patients who present to hospital emergency departments.
Johnson & Johnson released research this month showing that its system for robotic-assisted bronchoscopy helped physicians achieve an over 15% improvement in overall diagnostic yield compared to traditional bronchoscopy. This could mean that fewer patients will have to “wait and see” while their cancer potentially gets worse.
As more life-extending medications come on the market, health systems have a responsibility to make meaningful changes in how they screen and reach older adults. Earlier detection could mean millions of individuals enjoy longer lives of good cognitive health.
Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas.
Neko Health recently raised €60 million (about $65.8 million) in Series A financing. The Stockholm-based startup's medical scanning technology aims to conveniently and affordably collect extensive health data to aid doctors in catching diseases early. The company’s scan takes about 10 minutes and costs €250 (about $275).
Prana Thoracic, a startup focused on earlier detection and intervention for lung cancer, recently won the medical devices track of the MedCity News INVEST Pitch Perfect contest. The company is developing a minimally invasive electrosurgical device to help thoracic surgeons better excise smaller and intermediate-size lung nodules.
New York-based startup Ezra recently received FDA clearance for an AI tool it plans to use to launch “the world's first 30-minute full body MRI scan.” The tool, named Ezra Flash, enhances the quality of MR images so that radiologists can detect cancer earlier.
Ascertain — a healthcare AI company creation platform formed last year by Northwell Health and Aegis Ventures — has launched its first startup. New York-based Optain, which has gained an initial seed investment of $12 million, is an AI company meant to enable earlier disease detection and prevention through retinal imaging.
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
Early detection and treatment of heart failure can greatly improve an otherwise poor prognosis. Research from Mayo Clinic suggests artificial intelligence could be used to detect the condition even when no symptoms are present.
The Eko App uses automated disease detection software and is paired with the company's line of smart stethoscopes to analyze heart sounds with FDA-cleared AI algorithms. The redesigned app includes a range of new features to analyze heart sounds and cardiac rhythm for potential problems, the company said.
The Series B financing round was co-led by Merck Global Health Innovation Fund and Amgen Ventures. The company's Black female co-founders have prioritized overcoming systemic barriers to cancer prevention that have led to higher death rates for minorities.
Illumina originally spun off Grail in early 2017. Grail plans to launch its test for early detection of cancers, Galleri, next year. Illumina already owns 14.5% of the company, which it started in 2016.
The study design is still being finalized, and the company is thus not yet divulging too many details. However, CEO David Daly said it would be significantly larger than the previous DETECT-A, multi-center and would include both men and women.